Related Experiment Videos
Novel targets for Huntington's disease: future prospects.
Sarah L Mason1, Roger A Barker1,2
1John van Geest Centre for Brain Repair, slm64@cam.ac.uk.
Degenerative Neurological and Neuromuscular Disease
|July 28, 2018
Summary
Huntington's disease (HD) treatments are shifting towards neuroprotective compounds that target the disease's cause. This review examines emerging therapies in early clinical trials for this progressive neurodegenerative disorder.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Huntington's disease (HD) is an inherited, progressive neurodegenerative disorder.
- HD presents with a triad of motor, cognitive, and psychiatric symptoms.
- Current therapeutic strategies for HD have yielded limited significant advances despite numerous trials.
Purpose of the Study:
- To review the current status of novel therapeutic interventions for Huntington's disease.
- To discuss the supporting evidence for emerging HD treatments.
- To highlight treatments currently in early-phase clinical trials (Phase I/II).
Main Methods:
- Review of scientific literature on Huntington's disease pathogenesis and therapeutic development.
- Analysis of data from early-phase clinical trials for novel HD treatments.
- Focus on mechanistic-based interventions and neuroprotective compounds.
Main Results:
- A shift in therapeutic focus from symptomatic relief to disease-modifying strategies.
- Identification of several promising neuroprotective compounds and mechanistic interventions.
- Many novel HD therapies are progressing through early-stage clinical trials.
Conclusions:
- Emerging therapies for Huntington's disease show promise in targeting underlying pathogenesis.
- The development of neuroprotective compounds offers hope for slowing or halting HD progression.
- Continued research and clinical trials are crucial for advancing HD treatment options.